| Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib SW Han, TY Kim, PG Hwang, S Jeong, J Kim, IS Choi, DY Oh, JH Kim, ... Journal of clinical oncology 23 (11), 2493-2501, 2005 | 1002 | 2005 |
| Optimization of patient selection for gefitinib in non–small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt … SW Han, TY Kim, YK Jeon, PG Hwang, SA Im, KH Lee, JH Kim, DW Kim, ... Clinical Cancer Research 12 (8), 2538-2544, 2006 | 329 | 2006 |
| Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis B Keam, SA Im, KH Lee, SW Han, DY Oh, JH Kim, SH Lee, W Han, ... Breast Cancer Research 13, 1-7, 2011 | 307 | 2011 |
| Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma BH O’Neil, JM Wallmark, D Lorente, E Elez, J Raimbourg, C Gomez-Roca, ... PloS one 12 (12), e0189848, 2017 | 289 | 2017 |
| Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy, independent of body mass index Y Choi, DY Oh, TY Kim, KH Lee, SW Han, SA Im, TY Kim, YJ Bang PloS one 10 (10), e0139749, 2015 | 271 | 2015 |
| Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial MG Fakih, S Kopetz, Y Kuboki, TW Kim, PN Munster, JC Krauss, ... The Lancet Oncology 23 (1), 115-124, 2022 | 266 | 2022 |
| Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic … J Xu, TW Kim, L Shen, V Sriuranpong, H Pan, R Xu, W Guo, SW Han, ... Journal of Clinical Oncology 36 (4), 350-358, 2018 | 249 | 2018 |
| Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancer SW Han, PG Hwang, DH Chung, DW Kim, SA Im, YT Kim, TY Kim, ... International journal of cancer 113 (1), 109-115, 2005 | 217 | 2005 |
| Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer SW Han, DY Oh, SA Im, SR Park, KW Lee, HS Song, NS Lee, KH Lee, ... British Journal of Cancer 100 (2), 298-304, 2009 | 212 | 2009 |
| Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). JC Bendell, TW Kim, BC Goh, J Wallin, DY Oh, SW Han, CB Lee, ... Journal of Clinical Oncology 34 (15_suppl), 3502-3502, 2016 | 210 | 2016 |
| The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer J Rhee, SW Han, DY Oh, JH Kim, SA Im, W Han, I Ae Park, DY Noh, ... BMC cancer 8, 1-8, 2008 | 205 | 2008 |
| Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple … A Min, SA Im, DK Kim, SH Song, HJ Kim, KH Lee, TY Kim, SW Han, ... Breast Cancer Research 17, 1-13, 2015 | 186 | 2015 |
| Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing SW Han, HP Kim, JY Shin, EG Jeong, WC Lee, KH Lee, JK Won, TY Kim, ... PloS one 8 (5), e64271, 2013 | 179 | 2013 |
| RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib A Min, SA Im, YK Yoon, SH Song, HJ Nam, HS Hur, HP Kim, KH Lee, ... Molecular cancer therapeutics 12 (6), 865-877, 2013 | 167 | 2013 |
| KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach YK Yoon, HP Kim, SW Han, DY Oh, SA Im, YJ Bang, TY Kim Molecular Carcinogenesis: Published in cooperation with the University of …, 2010 | 166 | 2010 |
| Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for … RH Xu, K Muro, S Morita, S Iwasa, SW Han, W Wang, M Kotaka, ... The Lancet Oncology 19 (5), 660-671, 2018 | 158 | 2018 |
| Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive … HG Yi, HJ Kim, YJ Kim, SW Han, DY Oh, SH Lee, DW Kim, SA Im, TY Kim, ... Lung cancer 65 (1), 80-84, 2009 | 158 | 2009 |
| Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation A Sacher, P LoRusso, MR Patel, WH Miller Jr, E Garralda, MD Forster, ... New England Journal of Medicine 389 (8), 710-721, 2023 | 152 | 2023 |
| Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. DY Oh, SH Lee, SW Han, MJ Kim, TM Kim, TY Kim, DS Heo, M Yuasa, ... Cancer Res. Treat 47 (4), 607-15, 2015 | 146 | 2015 |
| A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors J Mateo, G Ganji, C Lemech, HA Burris, SW Han, K Swales, S Decordova, ... Clinical Cancer Research 23 (19), 5981-5992, 2017 | 145 | 2017 |
